Cargando…
Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907565/ https://www.ncbi.nlm.nih.gov/pubmed/35280250 http://dx.doi.org/10.3389/fphar.2021.787239 |
| _version_ | 1784665674592813056 |
|---|---|
| author | Isles, Michael P. |
| author_facet | Isles, Michael P. |
| author_sort | Isles, Michael P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8907565 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-89075652022-03-11 Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety Isles, Michael P. Front Pharmacol Pharmacology Frontiers Media S.A. 2022-02-24 /pmc/articles/PMC8907565/ /pubmed/35280250 http://dx.doi.org/10.3389/fphar.2021.787239 Text en Copyright © 2022 Isles. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Isles, Michael P. Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title | Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title_full | Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title_fullStr | Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title_full_unstemmed | Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title_short | Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety |
| title_sort | nanomedicines and nanosimilars—why a robust centralised regulatory framework is essential to enhance patient safety |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907565/ https://www.ncbi.nlm.nih.gov/pubmed/35280250 http://dx.doi.org/10.3389/fphar.2021.787239 |
| work_keys_str_mv | AT islesmichaelp nanomedicinesandnanosimilarswhyarobustcentralisedregulatoryframeworkisessentialtoenhancepatientsafety |